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1 |  OVERVIEW
Resources in oral health care are limited. As such, the im-
plementation of a new strategy, regardless of its nature—
preventive, diagnostic or treatment—typically involves the 
reduction or removal of another. Therefore, economic eval-
uation (EE) studies in dentistry are pertinent in allocating 
resources to the best strategies available; providing valuable 
information for policy leaders and clinicians involved in the 
decision-making process. The pioneering economic studies 
in the field of oral health date back to the 1960’s and as-
sessed the impact of water fluoridation on the cost of chil-
dren’s oral care.1
Although the late 20th century represented the starting 
point of economic research in dentistry, only in the 2000’s 
was a considerable increase in the number and quality of 
EE studies observed.2 Currently, in child oral health re-
search there remain relatively few EEs, though there is an 
upward trend in the number of EEs published each year in 
this field.3
2 |  BASIC PRINCIPLES OF 
ECONOMIC EVALUATIONS
There are a number of resources involved in health care, 
including people, time, equipment, facilities and knowl-
edge.4 These resources are not limitless, regardless of 
whether a healthcare system is publicly funded or based on 
social or private insurance. It is not practicable for every 
programme to be provided, and hence, a decision must be 
made to determine which programmes are the best value 
for money. Importantly, however, through the selection 
of a programme to fund, there exists an opportunity cost, 
whereby the benefit of an alternative programme will be 
forgone. The organisation tasked with making these deci-
sions must be provided with details surrounding the cost 
and consequences of all relevant alternative programmes to 
ensure their judgement is well-informed. EEs can provide 
decision-makers with the information required to enable 
them to maximise the benefits from healthcare spending; 
overcome regional variations in access; contain costs and 
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Economic evaluations play an important role in identifying the cost-effectiveness of 
alternative healthcare programmes, informing decisions surrounding funding and the 
allocation of resources. This paper outlines the basic principles of economic evalu-
ation and how it can be conducted alongside a clinical trial. Furthermore, it consid-
ers the ways in which evidence from these studies can be used, and the challenges 
researchers are faced with when conducting economic evaluations in the field of 
children’s oral health.
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manage demand; and provide bargaining power with sup-
pliers of healthcare products.5
An EE is typically defined as the comparative analysis of 
alternative courses of action in terms of both their costs and 
consequences.4 Studies that fail to compare two or more al-
ternatives, such as a cost analysis, or an outcome description, 
cannot be considered a full EE. Likewise, studies that do not 
attempt to compare the cost and consequences of a programme 
with an alternative do not meet the above definition and can 
only be considered a partial evaluation. Although partial evalu-
ations can still provide an important contribution to knowledge 
in this field, they cannot be used to answer questions relating to 
efficiency; that is, the achievement of acceptable efficacy and 
efficiency with the most appropriate use of resources.4,6
There are three main types of full EE, which vary in terms 
of outcome. The cost-benefit analysis (CBA) is the broad-
est form of analysis, characterised by the measurement of all 
benefits in monetary terms. CBA considers the wider social 
implications of a programme on the economy as a whole, in-
cluding the costs and consequences external to the healthcare 
sector.7 Through comparing the incremental benefits with the 
incremental costs, the net social benefit of the programme 
can be identified.4 Cost-effectiveness analysis (CEA) is the 
most common form of full EE. It compares the incremen-
tal cost of a programme, from a particular viewpoint, with 
the incremental health improvement attributable to the pro-
gramme; the latter being measured in natural units specific to 
the programme under analysis, such as a reduction in dmft/
DMFT. Conversely, the cost-utility analysis (CUA) measures 
benefits in terms of utilities. The most commonly used util-
ity-based measure is the quality-adjusted life year (QALY), 
which combines the quality of life and length of life gained 
as a result of a healthcare programme, into a single unit.
There is a fourth type of EE that has created some de-
bate as to whether it fulfils the definition of a full EE. The 
cost-minimisation analysis (CMA) is historically undertaken 
in a situation where there is no statistically significant differ-
ence between the consequences, or effectiveness, of the al-
ternative programmes. As such, only the costs are compared. 
CMA has been criticised as the assumption of equivalence 
overlooks any uncertainty surrounding consequences and 
fails to capture wider benefits of healthcare programmes.8,9
It is important to establish the perspective of an EE in the 
early stages of planning, as it may have implications for the 
trial design.10 Many EEs in healthcare take the perspective of 
the healthcare provider, which may be a national health care 
system (eg, the NHS in the UK), a health insurer or an inde-
pendent dental surgery. This relatively narrow perspective can 
be advantageous to groups that are concerned only with the 
impact and costs of an intervention within a specific organi-
sation.10 This approach can be widened to include the impacts 
on patients, which given the widespread nature of co-pay-
ments in dentistry is likely to be an important consideration 
for oral health evaluations. Nonetheless, broader approaches, 
termed societal approaches, are increasingly recommended.11 
These consider the impact of an intervention on the welfare 
of the whole of society, for example including costs such as 
the costs to employers from time off for dental appointments. 
Understandably, a more inclusive approach such as this can 
produce differences in cost-effectiveness; hence, it is nec-
essary for researchers to provide clarity on the perspective 
taken. Furthermore, a pragmatic view is sometimes required, 
as it may not be feasible to identify all the benefits and costs 
to society arising from an intervention.
3 |  COSTING
The common aspect of all EEs is the incorporation of cost. 
Although cost may appear to be less conceptually challeng-
ing than the different types of outcome measures used in EEs, 
it is still a potentially complex area. As already described, 
when cost is considered in economic terms, it is actually op-
portunity cost that is being measured. So, the cost that is of 
interest is the benefits forgone by using resources for one 
intervention or programme rather than the next best alterna-
tive. In order to understand the cost, the resources used are 
measured and are then usually reported in terms of their mon-
etary value. It is important here to clarify that negative out-
comes such as pain, distress, whereas often thought of by the 
public as costs, should be classified as negative outcomes/
benefits rather than costs, a common mistake in economic 
evaluations.12 If managing these negative benefits incurs a 
cost, however, these should be added to the costs. Equally, 
costs averted (or savings) should not be counted as benefits 
but negative costs.
Costs can be classified in different ways.13 The major clas-
sification splits direct and indirect costs where direct costs 
are those incurred by healthcare providers and patients in 
providing and accessing the healthcare such as consumables, 
staff time, equipment and estates; indirect costs usually con-
sist of productivity loss due to time away from work. Within 
direct costs, there are several other categories of costs: total 
cost will comprise all of the costs measured in an EE but this 
will depend on decisions about the perspective and scope of 
an evaluation, which will be explored further; fixed costs are 
those that remain the same irrespective of how many outputs 
are produced so for example, the cost of maintaining a dental 
surgery would not change by the number of patients treated; 
variable costs are those that vary with the number of out-
puts, so for example, the number of pre-formed metal crowns 
will vary depending on how many teeth are treated. Often the 
question of how much of something should be done is posed, 
and in these cases, the marginal cost becomes important, 
where this is the cost of producing one extra unit of output, 
for example restoring one more tooth.
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When a costing is being performed there are several im-
portant choices, the most important of which is the perspec-
tive that is being taken. Secondly, decisions about the scope 
of the exercise need to be considered; ideally all possible 
costs would be included but this is often difficult given that 
some costs may not be available or may be too time-consum-
ing to collect and so decisions need to be made. Each of these 
decisions should be justified and reported.14
Costing can generally be performed in one of two ways. The 
first way is micro-costing or bottom up, where resources used 
in providing a programme are identified and then individually 
costed. This can often be done prospectively in an EE along-
side a clinical trial. Alternatively, the top-down approach takes 
information from existing data sources such as nationally pub-
lished average data. The bottom up approach is usually more 
accurate, but more time-consuming and often a mixture of both 
approaches is used. Two particular types of costs may need 
special consideration and these are capital costs where there 
is a large upfront investment, often dealt with by annuitizing 
the initial outlay over the life time of the equipment but also 
factoring in depreciation and overhead costs, where some way 
of splitting the costs over outcomes of unit need to be justified 
and reported. Another methodological aspect of costing to be 
considered is discounting.15 Discounting reflects the fact that 
people have a time preference for costs such that they would 
usually prefer costs to be delayed and so costs that are further 
into the future are usually reduced by an appropriate discount 
rate. Many countries have their own discount rates, usually in 
the range of 3-5% per year. The final methodological aspect of 
costing is where there is uncertainty about the costs because 
data were poor or not available.16 This type of uncertainty, 
termed parameter uncertainty, can be dealt with by sensitivity 
analysis, which is dealt with later in this paper.
4 |  COST-EFFECTIVENESS 
ANALYSIS
Cost-effectiveness analysis facilitates decision-making by 
quantifying the trade-off between cost and effectiveness by 
jointly comparing the two. To allow for such comparisons, ef-
fectiveness must be measured for a single shared outcome that 
is measured in natural units, such as number of decayed teeth.
The cost and effectiveness of a proposed programme rel-
ative to some control case—no intervention or a competing 
intervention—is often graphically illustrated using the cost-ef-
fectiveness plane.17 The cost-effectiveness plane is a set of axes 
that present the additional, or incremental, cost and effective-
ness of the proposed programme relative to the control case on 
the y- and x-axes, respectively. There are five possible outcomes 
when comparing a proposed programme to a control case:
1. Both have the same effectiveness and cost.
2. The proposed programme is more effective and costs no 
more.
3. The proposed programme is less effective and costs no 
less.
4. The proposed programme is more effective and costs 
more.
5. The proposed programme is less effective and costs less.
Cost-effectiveness analysis is indifferent between the 
programme and the control case for Outcome 1. CEA unani-
mously prefers the programme that is simultaneously more ef-
fective and less expensive, which is the proposed programme 
for Outcome 2 and the control programme for Outcome 3. 
For both, the preferred programme is said to dominate the 
other programme. For Outcomes 4 and 5, a trade-off between 
cost and effectiveness is required.
The incremental cost-effectiveness ratio (ICER) is used to 
measure the size of the trade-off between two programmes. 
The ICER for two programmes, A and B, is the ratio of the 
differences in costs and the differences in effect:
Lower ICERs are preferred as a greater effect is achieved 
for a lower cost.
Decision-makers can set a threshold ICER which deter-
mines the minimum level of cost-effectiveness.18 Two met-
rics are used to report cost-effectiveness in relation to the 
threshold: the incremental net health benefit and the incre-
mental net monetary benefit. The incremental net health ben-
efit measures the additional health effect beyond the health 
effect of a programme with the same cost and the threshold 
ICER:
The incremental net monetary benefit measures the cost 
savings relative to a programme with the same effect size and 
the threshold ICER:
Although there are a number of methods available for set-
ting thresholds, it is argued that more research is needed into 
evidence-based approaches for establishing thresholds.
The greatest limitation of CEA is that only programmes 
aimed at achieving the same outcome can be compared. That 
vast majority of CEAs undertaken in paediatric dentistry 
focus on programmes aimed at the reduction of dental caries.3 
Even so, CEAs use a wide range of outcome measures in-













Incremental Net Health Benefit = ΔEffect −
ΔCost
Threshold ICER
Incremental Net Monetary Benefit = Threshold ICER × ΔEffect −ΔCost
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survival of molars24 and incidence of dental pain;25 hence, 
their findings are less comparable. To avoid this problem, the 
natural effect measure can be replaced by a standardised util-
ity measure as a generic measure of the benefits. By doing so, 
CEA becomes CUA and broader sets of programmes can be 
more readily compared.
5 |  MEASURING UTILITIES
Utility can be defined as  an individual’s preferences for 
health states under uncertainty.26 It is represented by cardi-
nal values, ranging from 1 (best health state possible) to 0 
(death), or even negative values for health states considered 
worse than death.27 The assessment of patients’ preferences 
in an EE provides the decision-maker with not only the results 
of improvement in oral health, but also the perspective of the 
individuals’ well-being. Utility values are used to obtain the 
effect measure in CUA and should ideally be determined by 
the highest sacrifice that a patient is willing to take in order to 
achieve a health state.28 There are diverse methods for meas-
uring utilities in clinical trials, and the pre-scored multi-attrib-
ute health status classification systems are the most common.
5.1 | Scaling methods
5.1.1 | Rating scale (RS)
Patients are instructed to rate the different health states and 
locate them on a scale, focusing on the interval between 
states rather than the value to which they correspond.29 The 
scale is usually a line with marked intervals, labelled with 
the best and worst outcomes.27 The RS reveals the indi-
viduals’ ranking of the health states and is simpler than 
choice-based methods to be used in clinical trials.4 One of 
the main disadvantages of the RS however is that its valua-
tion will vary depending on the context in which it is used 
(contextual bias).29
5.2 | Choice-based methods
5.2.1 | Standard Gamble (SG)
Subjects will choose between two alternatives: certainty of 
an intermediate health state; and the probability ‘P’ of a 
better health state or a ‘1 − P’ probability of a worse state.30 
The scenario is explained to the patient, and the probability 
‘P’ for the best health state varied until the patient is indif-
ferent between the certain health state and the gamble. The 
P value at which this indifference occurs is recorded and 
used as the patients utility for the intermediate state.30
5.2.2 | Time trade-off (TTO)
When using a TTO for states preferred to dead patients 
choose between two certain alternatives: living at full health 
for time t, or living at less-than-full health for time x (where t 
< x). The utility value is obtained by the variation of the time 
x until the patient is indifferent between the alternatives.4,30 
Similarly to the SG method, the TTO involves the idea of 
sacrifice, but here the main focus is the time for which a pa-
tient will maintain a health state.
5.3 | Pre-scored multi-attribute health 
status classification systems
Using the previously described utility measures in a clini-
cal trial is a complex task, as they are time-consuming and 
conceptually difficult. An alternative to this are the pre-
scored multi-attribute health status classification systems, 
generic measures of health-related quality of life (HRQoL) 
comprising different attributes of a health state and used 
to describe and value health.31 Each system will evaluate 
different attributes that are associated with an individual’s 
quality of life (pain, vitality, mobility, etc.) and utility 
scores for different responses have been derived already. 
The main issue with the use of these systems in dentistry 
is that they comprise attributes that are not usually affected 
by the main oral conditions, meaning the impact of oral 
conditions, such as dental caries, may not be detected.32 
Moreover, although some of the measures were designed to 
be responded by children, utility values were obtained from 
adult population. For this paper, we will briefly introduce 
the main pre-scored multi-attribute health status classifica-
tion systems developed for use in paediatric populations to 
obtain utility values for CUA.
5.3.1 | EQ-5D-Y
The EQ-5D is the most widely used generic preference-based 
measure and comprises five attributes (mobility, self-care, 
usual activities, pain/discomfort, anxiety/depression), with a 
new version containing a five-level scale (EQ-5D-5L).33 More 
recently, the EuroQoL group has taken steps to develop an 
adolescent version of the measure, known as the EQ-5D-Y.34
5.3.2 | HUI2
The Health Utilities Index Mark (HUI)-2 has seven attributes 
focused on children’s capacity (sensation, mobility, emotion, 
cognition, self-care, pain, fertility), with three, four or five 
levels.35 The HUI2 was developed for use in children with 
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cancer, and at present, there are no studies within paediatric 
dentistry using this measure to obtain utility values.
5.3.3 | AQoL-6D Adolescent
The Assessment of Quality of Life (AQoL)-6D Adolescent 
is based on the AQoL-6D, which was developed to comprise 
more dimensions than the existing measures. The adolescent 
version has six dimensions (independent living, pain, senses, 
mental health, happiness, coping, relationships, self-worth) 
with three or four items each and has not been applied to 
child oral health research.36
5.3.4 | CHU-9D
This is a descriptive child-centred, self-completed system for 
measuring health-related quality of life in children from 7 to 
11 years.37 The CHU-9D has nine attributes (worried; sad; 
annoyed; tired; pain; sleep; daily routine; work; able to join 
activities) with a five-level scale. Although it seems like a 
promising measure to be used in oral health research in pae-
diatric dentistry, a previous study has demonstrated that it 
cannot detect changes related to dental caries in children.32
Additional methods of obtaining patients preferences in 
clinical trials include discrete-choice experiments (DCE) and 
best-worst scaling (BWS).27 These are both multi-attribute 
choice-based methods and could be designed in different 
ways to elucidate adolescent patients’ preferences through or-
dinal data, as they are less cognitively demanding and do not 
have the same ethical concerns as SG or TTO (no mention of 
death/risk of death).
The utility values should be measured through a method 
that suits the health condition, with each method having 
advantages and disadvantages in trial-based CUA in pae-
diatric dentistry but none being ideal.38 Therefore, there is 
still a need for a child-centred utility measure for CUA in 
which children report on their own preferences. This would 
address the acknowledged need to actively involve children 
and young people in research and healthcare decisions.39,40 
Although the use of a child oral health-specific utility mea-
sure would negate one of the main advantages of the CUA 
that is the comparability between different fields.
In a CUA, once utility scores are derived (quality of health 
gain), they are combined with quantity. The most common 
outcome measure is the quality-adjusted life year (QALY), 
which is the product of the utility value of a health state and 
the time spent on that health state.26 According to a recent 
systematic review, only one study in child oral health re-
search reported outcomes in QALYs, although it is the main 
cited outcome measure for CUA in different national agen-
cies.3 The measurement of outcomes in QALYs however has 
a number of limitations, primarily in that all QALYs are con-
sidered equal, regardless of individual or situational circum-
stances.41 Furthermore, although the emphasis of QALYs is 
on quality of life, they fail to encompass other factors relating 
to well-being, or process attributes. Two oral health outcome 
measures for oral health research however have been derived 
from the QALY, the quality-adjusted tooth year (QATY) and 
the quality-adjusted prostheses years (QAPY), which incor-
porate tooth/prosthesis longevity and quality.42
Another outcome measure used in health care research is 
the disability-adjusted life year (DALY), a generic measure 
expressed as the number of healthy years lost due to a dis-
ability developed by the World Health Organization (WHO) 
to compare health across different countries. Moreover, the 
healthy-years equivalents (HYEs) were also proposed for 
CUA to overcome the concern regarding the QALY’s theo-
retical basis.43
6 |  COST-BENEFIT ANALYSIS 
AND MONETARY VALUATION
Although health state utility measures are widely accepted 
throughout health, outside of health it is common to value 
benefits in monetary terms. This method relies on measuring 
utility in terms of sacrifice with the sacrifice in this instance 
being measured in the common unit of money. Although 
using this common unit is appealing as it is conceptually eas-
ier than health state utilities, some have raised concerns about 
the ethical implications of valuing health in monetary terms. 
It has however been argued that monetary valuation is more 
in keeping with underlying economic theory and for dentistry 
it has been argued that it removes some of the problems that 
health state utility measures carry.44 Monetary valuation 
however brings its own concerns.45
In general, the technique of determining monetary val-
uations through ‘revealed preferences’, that is studying the 
amount people are willing to pay through observing what 
prices they have paid is rarely possible in health due to prices 
(co-payments) being altered by subsidy or tariffs from a true 
market rate. Instead, monetary valuation usually relies on 
‘stated preference’ where individuals are asked what they 
would hypothetically be willing to pay to receive health care 
or attain a health state if there was a free market for health 
care.46 This can either be done by directly asking for val-
ues using the contingent valuation method or by indirectly 
determining willingness to pay through a Discrete Choice 
Experiment. Although it is beyond the scope of this paper 
to outline either of these methods in detail, reviews of both 
methods in dentistry are available.47,48 In either method, the 
individual is not being asked what they think a fair price 
should be but what the maximum they would be willing 
to pay to reflect their value of something. In attaching a 
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monetary value, all aspects of the benefit derived from an 
intervention can be derived including non-health benefits. In 
addition, the respondent can incorporate any dis-benefits of 
an intervention/state for example pain or inconvenience into 
their valuation. At its simplest, If someone is willing to pay 
more for something, they value it more.
One of the common criticisms of willingness to pay is that 
it will be affected by ability to pay and so those with more 
money will be willing to pay more even at the same level of 
value or utility. This can be dealt with by checking for the in-
fluence of ability to pay (usually measured through income) 
on willingness to pay and then if necessary, weighting the re-
sults.49 In paediatric dentistry, an additional concern, as with 
health state utilities, is that it will be difficult or impossible 
for children to answer questions relating to the monetary val-
uation of health and usually parental valuations are relied on 
instead.
In order to use monetary valuations in a CBA, it is im-
portant to consider the perspective and whether patients are 
asked for values for their own care, the public are asked for 
values for the care directly or whether the public are asked for 
a societal valuation which would include the value of having 
the option of care available for themselves and others in the 
future.50 In the CBA, the simplest way to use the values is to 
subtract the costs in monetary from the benefit as measured 
by willingness to pay, leaving a net social benefit amount.
7 |  DECISION MODELLING 
VERSUS RANDOMISED 
CONTROLLED TRIALS
Randomised control trials (RCTs) are primarily concerned 
with the measurement and comparison of relevant outcomes 
between competing programmes. As the running of RCTs 
tend to incur large, fixed costs, the additional cost of col-
lecting cost data for an EE tends to be small relative to the 
benefits. Therefore, including an EE within a trial tends to be 
cost-effective.4 By combining the collection of cost and ef-
fect data within the trial’s framework, an EE can be delivered 
from a single RCT. This is termed trial-based EE. Data col-
lected through an RCT design is considered a valuable source 
of evidence as when a sufficient sample of patients is reliably 
randomised to the different programmes, the estimation of 
the average effect is unbiased and the study is said to have 
high internal validity. The collection of cost data within the 
RCT design extends the benefits of internal validity to the 
entire EE.
It is argued that for any EE to be appropriate for deci-
sion-making it should be relevant to the decision context with 
all relevant evidence included in the analysis.51 This can be 
achieved in part through a clear definition of the objective of 
the programmes, the target population and the inclusion of 
all relevant programmes, costs and benefits in the evaluation. 
Not all benefits and costs are realised immediately, so an ap-
propriate time horizon should be set to avoid underestimating 
any benefits or costs that are realised at later points in time. 
As evaluations contain a degree of imprecision, further anal-
yses should be conducted to characterise the effect of uncer-
tainty around estimates on the estimated cost-effectiveness of 
a programme to ensure robust decision-making takes place. 
Uncertainty can be due to variability in outcomes between 
identical patients termed stochastic uncertainty, variabil-
ity between patients based on their observed characteristics 
termed heterogeneity, structural uncertainty related to the 
choices made when using decision-analytic modelling which 
is discussed below, and the uncertainty in the estimation of 
parameters used in a decision model termed parameter uncer-
tainty.52 The analysis of this uncertainty also allows analysts 
to correctly recommend that further research is required be-
fore the final adopt or reject decision is made.
As trial-based EE benefits from the strengths of the RCT 
design, it also suffers from the potential weaknesses. If the 
trial sample of patients is not representative of the wider 
target population of the programme, then the study has low 
external validity or low generalizability to the decision con-
text. The high costs of RCTs may prohibit the inclusion of all 
relevant programmes and result in shorter time horizons.51 
Trial-based EE uses the RCT as the single source of evidence 
and therefore may ignore other relevant evidence.51 This may 
lead to incomplete information around uncertainty.51 Trials 
may also lead to artificially high compliance, and costs and 
benefit may be driven by the trial’s protocol.4
To avoid the limitations of using a single RCT for deci-
sion-making covered above, an alternate approach called 
decision-analytic modelling is used. Decision-analytic mod-
elling presents the options available to the decision-maker in 
a structured way as a set treatment pathways or movements 
between health states with outcome measures attached. The 
movement through pathways or between health states has 
probabilities attached allowing for the appropriate course 
of action to be chosen based on the expected benefits and 
costs of each available intervention. Decision-analytic mod-
elling incorporates evidence from multiple sources making 
trial-based EE a compliment rather than a substitute to deci-
sion-analytic modelling as one form of evidence for populat-
ing a model.51
The modelling process requires well defined and struc-
tured models. As models are simplifications of reality, the 
accuracy of a decision model is limited by the assumptions 
made regarding the structure. These assumptions should be 
justified by evidence to limit structural uncertainty.4
Rich comparisons of the available interventions can 
be made when a model is populated with parameters esti-
mated with strong evidence including the examination of 
heterogeneity between subgroups based upon clinical and 
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socio-demographic characteristics,53 the extrapolation be-
yond observed data to consider appropriate time horizons54 
and further sensitivity analyses. Sensitivity analysis involves 
varying one (one-way sensitivity) or more (multiway sen-
sitivity) parameter inputs, or the probability distribution of 
a parameter estimates (probabilistic sensitivity analysis) to 
measure the effect of parameter uncertainty on the cost-ef-
fectiveness of a programme. Sensitivity analyses can become 
more informative by drawing from sources of evidence be-
yond trials as the most important parameters can be more 
easily identified and the possible distribution of parameter 
inputs can be informed by evidence such as the policymakers 
or healthcare providers influence over the parameters when 
implementing a programme. Decision-analytic modelling al-
lows for the full evaluation of uncertainty in the model, which 
may result in the conclusion that more research is required 
before a decision is made.55
There are two main frameworks used in decision-ana-
lytic modelling: decision tree models and Markov models. 
Decision tree models map patient pathways onto probabil-
ity trees. Probability trees usually start with an initial choice 
node at which the intervention is chosen. The tree then splits 
to map possible patient pathways at chance nodes to differ-
ent outcomes each with a probability attached. For example, 
comparing school-based programmes for fluoride varnish 
and rinsing to a control case as the choice node and the dif-
ferences in the prevalence of enamel and dentin caries and 
the associated cost savings of avoided fillings as the chance 
nodes.56 Although most patient pathways can be represented 
by a decision tree, if events in the pathway are recurrent then 
a decision tree can become infinitely large. In this case, a 
Markov model is preferred.57 A Markov model allows for 
recurrent pathways by modelling the probability a patient 
moves between a finite set of health states. For example, the 
movement between a healthy state to an unhealthy state de-
fined by carious teeth and back to a healthy state after treat-
ment.58 If models require interactions between individuals or 
have large number of possible health states, then other meth-
ods may be required.57
8 |  HOW WE USE ECONOMIC 
EVALUATIONS
Economic evaluations answer questions of efficiency (ie, 
what is the best use of resources to maximize health). 
There are two types of efficiency questions with technical 
efficiency questions relating to comparisons of interven-
tions for the same outcome to determine which interven-
tion will produce the most output for a given resource and 
allocative efficiency questions revolving around whether 
a particular output should be produced or how much of it 
should be produced. So for example, whether we use one 
type of material or another for a restoration would be a 
technical efficiency question whereas whether we should 
invest in restorative care or periodontal care is an alloca-
tive efficiency question.
Cost-minimisation analysis, CEAs and CUAs can all help 
answer technical efficiency questions, and decisions are easy 
when one alternative is found to be less costly and more effec-
tive than an alternative. A more common situation however 
is that one alternative is more effective and more costly (ie, it 
has a higher ICER). In this case an allocative question must 
be asked as to whether there is something else that should be 
given up to invest in the better alternative. For allocative de-
cisions, in order to compare programmes with different out-
comes, a common unit of benefit is needed and so CUAs and 
CBAs are required. Even these however are still difficult to 
use in allocative decisions as a proper decision would require 
an understanding of the cost per QALY or net social benefit 
for all potential programmes.59 Even in a small field such as 
paediatric dentistry, it is very unlikely that this data will exist 
for all potential programmes and so decisions are often made 
with partial information which is unlikely to maximize effi-
ciency. Sometimes this decision-making will be aided by the 
use of a threshold such that all programme that have cost per 
QALY lower than the agreed threshold will be invested in but 
this may still result in more programmes being recommended 
than the total budget can fund.60 Alternative approaches to 
allocative decisions have been suggested including integer 
programming,12,61 or more pragmatic multi-criteria deci-
sion analysis tools such as programme budgeting and mar-
ginal analysis,62 although there have been very few uses in 
dentistry.63,64
9 |  SPECIFIC ISSUES IN 
DENTISTRY AND CHILD ORAL 
HEALTH RESEARCH
EEs in child oral health research are insufficiently reported.3 
The use of guidelines offers a means of addressing this issue 
by indicating the crucial aspects needed for a high-quality 
EE and standardising reports. Checklists are available for the 
conduct and reporting of EEs, such as the Drummond check-
list65 and the Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) statement, respec-
tively.14 The CHEERS format is based on the CONSORT 
(Consolidated Standards of Reporting Trials) and is endorsed 
by the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) in its latest report of good re-
search practices for trial-based CEAs.66
As mentioned earlier, the key problem with CEA in 
dentistry relates to the lack of comparability of the find-
ings through the use of a broad range of clinical outcome 
measures; a particular concern in caries research. This can 
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prevent data from being maximised through systematic re-
views and ultimately disrupts the dissemination of study 
findings across the world.67,68 This led to the commence-
ment of the Outcomes in Trials for Management of Caries 
Lesions (OuTMaC) study, which aims to develop a core 
outcome set for trials investigating clinical management of 
caries lesions in primary or permanent teeth.69 This may 
improve the measurement of benefits in CEA within child 
oral health research.
Despite the advantages in terms of comparability, in 
dentistry, there may be a number of difficulties in generat-
ing QALYs. For example, if an programme has an effect on 
only one tooth, such as a type of restoration, it would not 
be possible to determine whether the reported impacts re-
lated to that particular tooth, or another tooth in the mouth, 
or perhaps another oral health problems that they may be 
experiencing, such as oral ulcers.70 Moreover, it is acknowl-
edged that many children do not experience symptoms from 
carious primary teeth, there is unlikely to be a notable gain 
in QALYs noted following provision of an programme to 
address the caries.71,72 For these reasons, a preference-based 
measure suitable for the condition and population in ques-
tion may be more applicable to oral health promotion strat-
egies, rather than individual tooth-level programmes, to 
increase the sensitivity of preference-based instruments, 
allowing for changes in QALYs to be identified.
Although the conception of QATYs initially offered po-
tential for CUA, there has been little development over the 
years. Since utilities for four different tooth states were orig-
inally published,73 our knowledge of caries has increased 
substantially. Importantly, it is now understood that the dis-
ease is a dynamic process, moving between demineralisation 
and remineralisation;74 hence, these utilities are unlikely to 
reflect the full range of dental states represented on the car-
ies continuum. Furthermore, its applicability to the primary 
dentition has not yet been explored, nor has its comparability 
across different programmes.75 Moreover, the QATY may 
fail to acknowledge the wider impacts of caries beyond the 
tooth itself. These limitations currently preclude the wider 
use of the QATY as the primary means of measuring the ben-
efits of dental programmes.
It should be acknowledged that a substantial amount of 
funding is required to conduct clinical trials. This cost is even 
greater when investigating a condition such as dental caries, 
which may take years to develop. This is one of the key fac-
tors precluding the undertaking of EEs alongside clinical tri-
als and demonstrates the need for decision modelling studies 
in oral health research.
Importantly, the decision-making processes in dentistry 
are often not as centralised as in other areas of healthcare. In 
many health systems, for example, decisions surrounding the 
funding and implementation of oral health promotion strate-
gies are undertaken at a local level. Although this approach 
can help to ensure that services are tailored to meet the re-
quirements of the local population, an absence of centralised 
decision-making can lead to regional variation, which may 
serve to increase inequalities further.
10 |  CONCLUSION
Economic evaluation is an important aspect of understanding 
clinical interventions and programmes in paediatric dentistry. 
Any economic evaluation must carefully measure both costs 
and consequences, both of which require several considera-
tions. The measurement of outcomes is particularly difficult 
in paediatric dentistry, and further work is required in the 
field of utility measurement. Although economic evaluations 
can be done alongside a clinical trial, this is often difficult 
in oral health and modelling-based approaches may be more 
appropriate in some instances.
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